## Eculizumab (Soliris)

**Provider Order Form rev.** 10/03/2024

PATIENT INFORMATION	<b>Referral Status:</b>	□ New R	eferral	Updated Or	rder	Order Renewal
Patient Name:		DOB:		Patient Ph		
Patient Address:			Patie	nt Email:		
Allergies:		🗆 NKDA	Weight	(lbs/kg):	He	ight (in/cm):
Sex:  M /  F Date of Last Infusion:	Next Due Date:		Prefe	erred Location:		
DIAGNOSIS (Please provide ICD-10 code in space	e provided)					
generalized myasthenia gravis without exacerbatior	ו:	Neuromy	elitis Opt	ica (NMOSD):		
Other: Descrip	otion:					
REQUIRED INFORMATION MenACWY: Date of 1st dose: Brand: Date of 2nd dose: Brand: Meb B: Date of 1st dose: Brand: Date of 2nd dose: Brand: ( <i>Trumenba only</i> ) Date of 3rd dose: Prophylactic antibiotics prescribed: □ Yes / □ No Date patient started prophylactic antibiotics ( <i>if applicab</i> Provider REMS ID:	C	l Solumedro	500mg / [ 10mg PO ng [] PO / ] 25mg / [ I [] 40mg	] 650mg PO		-
<ul> <li>□ For gMG diagnosis: Patient is anti-acetylcholine recept positive (provide documentation)</li> <li>□ For NMSOD diagnosis: Patient is anti-aquaporin-4 (AQ positive (provide documentation)</li> <li>□ For gMG diagnosis: Meningococcal vaccine(s) given or date. First Soliris dose may be given at I later unless otherwise specified.</li> <li>THERAPY ADMINISTRATION &amp; DOSING (Chool = Administra couling the following the documentation)</li> </ul>	1P4) antibody 1 east 2 weeks Ca <b>ose one)</b> 모	• Sign as: I Ensure pati ard. I Provide nu	o Hea stiff o Mu: with ient carrie rsing care	dache with (1) fe neck/back scle aches with fl nout rash, confus s and understand per Nursing Proc	or meni ever, (2 lu-like s sion or ds Patie cedure,	ent Safety Information
<ul> <li>□ Administer eculizumab (Soliris) 900mg weekly<sup>1</sup> x4 dose 90 ml 0.9% sodium chloride (<i>final volume 180 ml</i>) and inf minutes.</li> <li>□ Administer eculizumab (Soliris) 1200mg for the fifth do after the fourth dose (week 5), then every 2 weeks<sup>1</sup> there with 120 ml 0.9% sodium chloride (<i>final volume 240 ml</i>) a over 35 minutes.</li> <li>☑ If infusion is stopped for any reason, total infusion time</li> </ul>	ouse over 35 of A ose one week eafter. Dilute and infuse	DDITION	-	-		
exceed 2 hours Monitor patient for hypersensitivity reaction for a peri minutes following each infusion <sup>1</sup> Recommended dosage time intervals; may adjust +/- 2 days if n	od of 60					
PROVIDER INFORMATION						
Preferred Contact Name:		Pref	erred Co	ntact Email:		

Preferred Contact Name:	Preferred Contact Email:				
Ordering Provider:	Provider NPI:				
Referring Practice Name:	Phone:	Fa	x:		
Practice Address:	City:	State:	Zip Code:		

## **REQUIRED DOCUMENTATION CHECKLIST** (Additional documentation required for processing and insurance approval)

**Required Documentation:** Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications, Disease status, MRI, Flow Cytometry, MG classification, MG-ADL score, EMG results **Required Labs:** Anti-Ach receptor, Anti-AQP4,

Provider Name (print)

**Provider Signature**